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Disposition of total and unbound prednisolone in renal transplant
patients receiving anticonvulsants. Kidney transplant patients receiving
phenytoin or phenobarbital may have decreased graft survival. These
drugs have been shown to enhance the metabolism of glucocorticoids.
We determined the disposition of total and unbound prednisolone in six
stable kidney transplant patients receiving prednisone for immunosup-
pression and phenytoin or phenobarbital for a seizure disorder. Six
similar patients not on anticonvulsants served as controls. A single
intravenous dose of prednisolone was administered, and plasma sam-
ples were analyzed for prednisolone using a high-performance liquid
chromatographic assay. Equilibrium dialysis was used to determine
unbound prednisolone concentrations. Pharmacokinetic analysis
showed that the half-life of prednisolone was shorter in the anticonvul-
sant group compared to the controls, based on both total (2.3 0.4 vs.
3.4 0.2 hr(sD), P <0.01) and unbound(1.7 0.3 vs. 2.4 0.2 hr, P <
0.01) concentrations. Total drug clearance was 10.4 2.8 liters/hr
(0.171 0.087 liters/hr kg) in the anticonvulsant group versus 7.2
1.2 liters/hr (0.100 0.014 liters/hr kg) in the controls (P < 0.05).
Unbound prednisolone clearance was 57.2 12.1 versus 46.4 8.7
liters/hr (P > 0.05) and for weight-corrected estimates 0.886 0.224
liters/hr kg versus 0.644 0.115 liters/hr-kg (P < 0.05) in the two
groups, respectively. Thus, the disposition of prednisolone is altered by
anticonvulsants in kidney transplant patients and may require dose
alteration.
Disparition de Ia prednisolone totale et libre chez des transplantés
rénaux recevant des anticonvulsivants. Les transplantés rénaux recevant
de Ia phenytolne ou du phCnobarbital pourraient avoir une survie du
greffon diminuée. Ces médicaments se sont avérés capables de stimuler
le mCtabolisme des glucocorticoldes. Nous avons déterminé l'élimina-
tion de Ia prédnisolone totale et libre chez six transplantés rénaux
stables recevant de Ia prCdnisone pour leur immunosuppression et de Ia
phénytoine ou du phénobarbital pour une épilepsie. Six malades
identiques sans anticonvulsivants ont servi de contrOle. Une dose
unique intraveineuse de prddnisolone a été administrCe, et des échantil-
ions plasmatiques ont été analyses pour Ia prédnisolone en utilisant un
dosage par chromatographie liquide a haute pression. Une dialyse a
l'Cquilibre a eté utilisée pour determiner les concentrations de prédniso-
lone non liée. L'analyse pharmacocinétique a montré que Ia demi-vie de
Ia prédnisolone Ctait plus courte dans le groupe aux anticonvulsivants
par rapport aux contrôles, qu'il s'agisse des concentrations totales (2,3
0,4 contre 3,4 0,2 hr (sn), P < 0,01) ou libres (1,7 0,3 contre 2,4
0,2 hr, P < 0,01). La clearance totale du mCdicament était de 10,4
2,8 litres/hr (0,171 0,087 litres/hr kg) dans le groupe anticonvulsi-
vant contre 7,2 1,2 litres/hr (0,100 0,014 litres/hr - kg) chez les
contrôles (P < 0,05). La clearance de Ia prédnisolone non liée était de
57,2 12,1 contre 46,4 8,7 litres/hr (P > 0,05), et après correction
pour le poids de 0,886 0,224 litres/hr- kg contre 0,644 0,115
litres/hr• kg (P < 0,05) dans les deux groupes, respectivement. Ainsi,
l'élimination de Ia prédnisolone est altérée par les anticonvulsivants
chez les transplantés rénaux et peut imposer des modifications de Ia
dose.
Retrospective studies [1, 2] and case reports [3] have indicat-
ed that renal graft survival is decreased in kidney transplant
patients receiving anticonvulsant medications such as pheny-
tom and phenobarbital. Other studies [4—12] in healthy volun-
teers and patients (with various disease states) have shown that
the plasma clearance of various glucocorticoids (dexametha-
sone, hydrocortisone, methyiprednisolone, and prednisolone)
is increased in the presence of these anticonvulsants, presum-
ably due to stimulation of hepatic drug metabolizing enzymes.
Thus, decreased graft survival in transplant patients receiving
anticonvulsants may be related to increased metabolism of
prednisolone. Previous studies of glucocorticoid metabolism
[4—12] were based only on measurement of total (bound and
unbound) glucocorticoid concentrations. Determination of un-
bound prednisolone concentrations is important since predniso-
lone exhibits concentration-dependent pharmacokinetics [13—
16], and it is the unbound drug which is believed to be
pharmacologically active [17, 18],
The objective of this study was to compare the pharmacoki-
netic disposition of total and unbound prednisolone (the active
metabolite of prednisone) in kidney transplant patients receiv-
ing anticonvulsants with a control group of patients. We found
that anticonvulsants increased the clearance of both total and
unbound prednisolone.
Methods
Study design. The present study included six clinically stable
patients who had received a kidney transplant and were taking
anticonvulsants and six similarly matched control transplant
patients. The study was approved by the Committee on Human
Research of the University of California at San Francisco.
Individual patient characteristics are shown in Table 1 and
anticonvulsant dosage regimens are shown in Table 2. All
patients on anticonvulsants had been taking these drugs regular-
ly for 5 weeks to 6 years. One patient (A4, C4) participated in
both control and treatment groups, once prior to phenytoin
119
Received for publication March 8, 1983
and in revised form June 21, 1983
© 1984 by the International Society of Nephrology
120 Gambertoglio et a!
a C/NC represents cushingoid/noncushingoid.
b The values represent the pre-study dose concentrations.
Table 1. Patient characteristics
Table 2. Anticonvulsant dosage regimen
Plasma
Patient
no. Anticonvulsant
Dose
mg/day
concentration
mg/liter
Al Phenytoin 400 18
A2 Phenytoin 300 7
A3 Phenytoin
Phenobarbital
400
90
8
17
A4 Phenytoin 300 12
A5 Phenobarbital 60 6
A6 Phenobarbital 60 13
treatment and again 5 weeks after its initiation. All patients had
satisfactory kidney function and tests of liver function and
serum albumin levels were in the normal range for both groups.
In addition to their single daily maintenance dose of prednisone,
patients were receiving azathioprine and various other drugs.
However, no patients were taking any other medication known
to alter drug metabolism.
Each patient received a single intravenous bolus dose of
prednisolone (similar to their usual oral prednisone dose, or 0.2
mg/kg) as prednisolone sodium phosphate, Hydeltrasol®
(Merck, Sharp & Dohme, West Point, Pennsylvania; see Table
3 for doses). Venous blood samples, 10 ml each, were obtained
before the intravenous dose and at 0.04,0.08,0.17,0.25,0.5, 1,
2, 3, 4, 6, 8, 10, and 12 hr after the dose. Blood samples were
collected in heparinized Vacutainer® tubes (stoppers removed)
and immediately centrifuged; the plasma was harvested and
then frozen at —70°C until assayed.
Assay and protein binding. Prednisolone and hydrocortisone
concentrations in plasma were determined using a specific high-
performance liquid chromatographic (HPLC) assay [19]. This
assay allows the simultaneous measurement of these glucocorti-
coid compounds. The lower limit for routine analysis was 10
ng/ml. The intraday variability was 1 to 3% and the interday
variability was 3 to 10% (coefficient of variation).
Patient Age Weight
Serum
creatinine
Time since
transplant
Daily prednisone
dose/duration
Peak hydrocortisone
concentrationb
no. years Sex kg mg/dl months C/NC° mg/months ng/ml
Anticonvulsant group
Al 22 M 51 1.0 25 NC 15/25 144
A2 32 M 64 1.8 67 NC 15/52 79
A3 18 M 85 2.6 12 C 35/6 91
A4 27 M 84 1.1 39 NC 30/0.5 27
AS 38 M 70 1.6 23 NC 15/3 14
A6 16 M 45 1.1 3 NC 30/1.5 44
Mean 26 66 1.5 28 67
so 8 16 0.6 23 48
Control group
Cl 56 M 78 1.6 18 NC 15/5 35
C2 30 F 82 2.6 23 C 20/8 <10
C3 28 M 60 1.1 13 NC 12.5/0.5 <10
C4 27 M 81 1.1 38 NC 15/1 17
CS 43 M 62 1.6 2 NC 30/0.5 114
C6 35 M 70 2.0 10 NC 20/4 <10
Mean 37 72 1.7 17 33
SD 11 10 0.6 12 41
The plasma protein binding of prednisolone was determined
in all plasma samples by equilibrium dialysis [20]. Briefly, 0.5
ml of plasma was equilibrated against 0.5 ml of isotonic Krebs-
Ringer buffer (pH 7.4) containing [6,7(n)-3H] prednisolone at
37°C for 16 hr. Calculations of the bound and unbound prednis-
olone concentrations postdialysis were made correcting for the
redistribution of drug and volume changes occurring during the
dialysis procedure [21].
Data analysis. Protein binding. The binding of prednisolone
to plasma proteins is concentration-dependent [14, 20—22] and
may be described by the following function:
= + S P (1)
where nd is the concentration of bound prednisolone and P is
the unbound concentration after dialysis; CAP1 and KD1 are the
binding capacity and dissociation constant of a saturable bind-
ing site (transcortin), and S is the ratio of capacity to dissocia-
tion constant (CAP2/KD2) of a nonsaturated binding site (albu-
min). After estimates of the binding parameters CAP1, KD1,
and S for prednisolone were obtained from each study patient,
the unbound concentration was derived from the equation:
=
B + + 4 A KD1 P1o1 (2)
2A
where P is the estimate of the unbound concentration of
prednisolone in vivo, B = (P10 — CAP1 — KD1 A), A = 1 + S,
and Pt01 is the total concentration of prednisolone measured in
the patient's plasma by HPLC prior to equilibrium dialysis.
Protein binding parameters were estimated using unweighted
nonlinear least squares regression [23].
Pharmacokinetics. A two-compartment model with bolus
input was used to describe plasma prednisolone concentrations
of total and unbound drug. The pharmacokinetic parameters of
prednisolone were estimated using nonlinear least squares
regression [24]. Observed concentrations were weighted by the
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Table 3. Pharmacokinetic parameters of total prednisolone
Prednis-
olone
Patient dose
no. mg
T112
hr
CL
liters/hr
CL
liters!
hr kg
V,
liters
V,
liters/kg
Anticonvulsant group
Al 12.3
A2 12.5
A3 17.0
A4 16.4
A5 15.0
A6 30.0
Mean 17.2
SD 6.6
1.9
2.1
2.6
2.6
2.8
1.8
2.3
0.4
9.7
8.4
11.9
7.8
9.4
15.3
10.4
2.8
0.191
0.132
0.140
0.093
0.133
0.337
0.171
0.087
23.2
23.3
37.2
28.1
36.0
33.2
30.2
6.2
0.46
0.37
0.44
0.34
0.51
0.73
0.47
0.14
Control group
Cl 15.0
C2 17.5
C3 15.0
C4 16.0
C5 15.0
C6 15.0
Mean 15.6
so 1.0
3.1
3.6
3.5
3.2
3.2
3.6
3.4
0.2
9.0
8.3
6.7
6.1
6.2
6.8
7.2
1.2
0.116
0.100
0.111
0.076
0.101
0.096
0.100
0.014
39.4
40.3
32.2
27.6
23.8
34.9
33.0
6.6
0.51
0.49
0.53
0.34
0.38
0.50
0.46
0.08
ft test
Mann-Whitney <
0.0003
0.01
0.026
<0.05
0.077
< 0.05
0.452
> 0.05
0.828
> 0.05
reciprocal of the value squared. Half-life was calculated by
dividing 0.693 by the terminal elimination rate constant (Xz)
estimated from the pharmacokinetic model. The area under the
plasma concentration-time curve (AUC) was obtained using the
log-trapezoidal rule and the remaining AUC beyond the last
measured data point was estimated by dividing the predicted
value for the last data point by Xz [241. Estimates of plasma
clearance (CL) and volume of distribution at steady state (V)
were calculated using the noncompartmental equations:
and
DoseCL AUC
= Dose (AUMC)/(AUC)2
where AUMC is the area under the first moment of the plasma
prednisolone concentration-time curve, using the log-trapezoi-
dal rule [25, 26].
Statistical analysis. Statistical comparisons between the two
patient groups were made using the t test on unpaired data and
the Mann-Whitney Rank Sign Test on the PROPHET computer
system [27]. Both tests were applied to all comparisons and a
statistically significant difference was defined as P < 0.05. If
disagreement was observed, the results of the nonparametric
test were used to determine significance. Results are reported
as mean SD.
Results
The pharmacokinetic parameters based on total prednisolone
concentrations are listed in Table 3. A significantly shorter
mean prednisolone half-life of 2.3 0.4 hr was observed in the
(3)
Table 4. Prednisolone binding parameters
Patient group CAP1 ng/ml KD1 ng/ml S
Anticonvulsant 210 53.6 18.7 8.1 1.4 0.5
Control 187.5 113.6 17.3 8.3 2.0 0.9
ft test
lMann-Whitney
0.66
> 0.05
0.78
> 0.05
0.14
> 0.05
a Values are mean SD.
anticonvulsant group, compared to 3.4 0.2 hr in the control
patients. This was accounted for by a significant increase in
total plasma drug clearance, 10.4 2.8 liters/hr (0.171 0.087
liters/hr . kg) versus 7.2 1.2 liters/hr (0.100 0.014 li-
ters/hr kg) in the two respective groups. No differences were
noted in mean steady-state volume of distribution between the
two groups. Figure 1 illustrates the plasma prednisolone con-
centration-time profile for total drug in the one patient (A4, C4)
who was studied in the presence and absence of phenytoin.
In Table 4 are summarized the protein binding parameters of
prednisolone. No significant differences were observed in val-
ues for CAP1, KD1, and S of prednisolone in the two groups of
patients.
Table 5 lists the pharmacokinetic parameters based on un-
bound prednisolone concentration. A significant decrease in
half-life for the anticonvulsant group was found, being 1.7 0.3
hr versus 2.4 0.2 hr in the control patient group. For the
anticonvulsant group unbound prednisolone clearance was
higher, 57.2 12.1 liters/hr versus 46.4 8.7 liters/hr (P >
0.05); and for weight corrected values, 0.886 0.224 li-
ters/hr kg versus 0.644 0.115 liters/hr kg (P < 0.05).
Steady-state volume of distribution was lower, 101.1 33.2
liters (1.53 0.39 liters/kg) versus 145.7 40.9 liters (2.03
0,67 liters/kg) compared to the controls. However, these differ-
ences were not statistically different. Figure 2 illustrates the
plasma prednisolone concentration-time profile for unbound
drug in the same patient as is shown in Figure 1. Note the
greater differences in drug concentrations observed between
the two study conditions compared to that using total predniso-
lone concentrations.
Patients receiving anticonvulsants exhibited higher mean
(4) morning (pre-dose) hydrocortisone peak concentrations of 6748 nglml than did control patients with 33 41 ng/ml (Table 1).
Analysis of all plasma samples obtained during the pharmacoki-
netic study for hydrocortisone concentration above the detec-
tion limit of 10 ng/ml revealed that hydrocortisone was present
almost twice as often in the anticonvulsant group, 22% (16 out
of 72 samples), compared to controls, 13% (10 out of 77
samples).
Discussion
In 1977, Wassner et al [2] reported results of a retrospective
study showing that the 1- and 2-yr graft survival for 25 grafts in
patients on anticonvulsant medication was 32 and 6%, respec-
tively, compared to 76 and 67% in 127 control grafts. Phenobar-
bital was the primary anticonvulsant used, although some
patients required phenytoin or ethosuximide.
Our clinical observations, as well as that of other investiga-
tors [3], agree with the findings of Wassner et al [2], that good
allograft function can be more difficult to maintain in transplant
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0
Time, hours
Fig. 1. The plasma total prednisolone concentration-time profile in
patient A4,C4 studied in the presence (•) and the absence (0) of
phenytoin.
Anticonvulsant group
Al 1.5 66.9 1.315
A2 1.6 44.9 0.706
A3 1.8 71.8 0.845
A4 1.7 59.8 0.715
A5 2.1 58.4 0.833
A6 1.4 41.1 0.904
Mean 1.7 57.2 0.886
SD 0.3 12.1 0.224
Control group
CI 2.4 50.6 0.649
C2 2.4 54.3 0.660
C3 2.8 50.2 0.832
C4 2.4 47.5 0.587
CS 2.2 29.5 0.479
C6 2.5 46.2 0.656
Mean 2.4 46.4 0.644
SD 0.2 8.7 0.115
0.107
> 0.05
0.040
< 0.01
Jt test 0.0003
lMann-Whitney < 0.01
patients on anticonvulsants and greater doses of prednisone
may be required. Wassner et al [2] noted that in two patients in
whom anticonvulsant medication could not be discontinued, the
daily doses of prednisone needed were greater than 1 mg/kg.
Several studies in healthy volunteers and patients having a
variety of disease states have reported the effect of phenytoin or
phenobarbital on increasing the metabolism of glucocorticoids
and/or decreasing its clinical effects [4—12]. Sells et a! [5] found
the half-life of methylprednisolone significantly shorter in kid-
ney transplant patients receiving phenobarbital or phenytoin for
a seizure disorder with or without a functioning allograft,
compared to controls. Petereit and Meikle [41 studied the effect
of 3 weeks of phenytoin administration on prednisolone phar-
macokinetics in five healthy subjects. The clearance of prednis-
olone increased by 77 46% of the baseline value of 1.16
0.29 mI/mm/kg, and half-life decreased by 45 9.2% of the
v, control value of 3.2 0,4 hr. Distribution volume and bioavail-
liters liters/kg ability of prednisolone were not significantly altered by the
phenytoin.
93.1 1.83 Unlike previous studies [4—12], we were able to measure the
73.9 1.16 concentration of unbound prednisolone in plasma as well as
107.6 1.27 total drug concentrations. Because the protein binding of pred-
121.6 1.45 nisolone changes with concentration, clearance estimates based
on total drug concentrations are misleading, since they are
101:1 1:53 confounded by the variation in binding [14]. Both total and
33.2 0.39 unbound prednisolone plasma half-life were significantly
shorter in the anticonvulsant group. When based on total drug,
158 8 2 04
this decrease in half-life was accounted for by a corresponding
156:8 1:91 significant increase of approximately 44% in plasma clearance,
187.6 3.11 from 7.2 1.2 to 10.4 2.8 liters/hr (71% increase for weight-
138.4 1.71 corrected values; Table 3). No change in steady-state volume of
68.8 1.11 distribution was observed. The difference in plasma clearance is
similar to that found by Petereit and Meikle [41 in their healthy
40.9 0:67 subjects. However, if the patient (A6) who received the largest
prednisolone dose (who also had the largest total clearance) is
0.065 0.138 excluded, then the increased clearance in the anticonvulsant
> 0.05 > 0.05 group is only 31% (38% using weight-corrected estimates). The
higher total clearance due to the higher dose in this patient is
consistent with the concentration-dependent pharmacokinetic
disposition of this drug [14—16].
With regard to unbound prednisolone concentrations, drug
clearance, and distribution volume, differences in these param-
eters between the two groups are in a direction consistent with
the significant change in half-life, that is, clearance increases,
and volume decreases in the anticonvulsant group. Unbound
prednisolone clearance was 46,4 8.7 liters/hr in the control
patients and 57.2 12.1 liters/hr in those on anticonvulsants, a
difference of 23% (Table 4). The weight-corrected estimates of
unbound clearance exhibited a significant difference of 38%
between the two groups. This is approximately half that ob-
served for differences in estimates of clearance based on total
drug concentrations. Reasons for a lower mean steady-state
volume of distribution in the anticonvulsant group compared to
2C0-
C
. .9
—c
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F—0
10000
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5—CC00)
-c c9°
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.0 CCo
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1000
100
10
2 4 6 8 10 12
Without
Table 5. Pharmacokinetic parameters of unbound prednisolone
4 6 8 10 12
Time, hours
CL
T112 CL liters!
Patient no. hr liters/hr hr' kg
Fig. 2. The plasma unbound prednisolone concentration-time profile in
patient A4,C4 studied in the presence (•) and the absence (0) of
phenytoin.
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the controls are unknown. No significant differences were
observed in the in vivo plasma protein binding parameters of
prednisolone in the two groups. At the receptor level, Ballard et
a! [281 have shown that phenobarbital and phenytoin inhibit
binding of 3H-dexamethasone by glucocorticoid receptors of rat
hepatoma (HTC) cells only when they are at toxic-to-lethal
concentrations. For the patients in our study, plasma concen-
trations of phenytoin and phenobarbital were either within or
slightly below the therapeutic range (Table 2).
Petereit and Meikie [41 observed that in healthy subjects the
average oral dose of prednisolone needed to suppress the 8A.M.
plasma hydrocortisone level to 50 ng/ml was approximately
doubled after phenytoin. It is interesting to note that our
patients on anticonvulsants had over a twofold greater mean
morning peak hydrocortisone concentration. Measurable hy-
drocortisone levels were also found almost twice as often in
plasma samples obtained during the study, compared to the
control group. This apparently reflects less suppression of the
hypothalamic-pituitary-adrenal axis and a more normal circadi-
an rhythm of endogenous steroid production.
In conclusion, the disposition of prednisolone is altered in
kidney transplant patients receiving phenobarbital or pheny-
tom. A significantly shorter half-life is observed for total and
unbound prednisolone. However, the increase in plasma clear-
ance based on unbound prednisolone is 23 to 38%, which is less
than that observed for total drug concentrations, 44 to 71%.
Thus, the reported differences in therapeutic response in pa-
tients taking anticonvulsants may not be explained entirely by
increased unbound corticosteroid clearance, and additional
factors are involved in determining the appropriate steroid dose
in these transplant patients.
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